Tokyo: June 7, 2019 - TOA EIYO Ltd. (President: Atsuo Takahashi, Ph.D., “TOA EIYO”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that Bisono® Tape 2 mg (non-proprietary name: bisoprolol), a transdermal patch containing a β1 blocker has been launched in Japan, The patch is a new strength of Bisono® Tape intended for flexible dose-adjustment in atrial fibrillation treatment.

Bisono® Tape was co-developed by TOA EIYO and Nitto Denko Corporation (TSE: 6988, President and CEO: Hideo Takasaki). Bisono® Tape 4 mg and Bisono® Tape 8 mg were launched in September, 2013 in Japan as the world’s first transdermal medication for essential hypertension (mild to moderate cases) containing 4 mg and 8 mg of bisoprolol, a β1 blocking agent, respectively. 
In January 2019, the Bisono® Tape 4 mg and 8 mg were approved in Japan for the new indication of atrial fibrillation, and the new strength, Bisono® Tape 2 mg received approval for atrial fibrillation as well. Furthermore, the formulations for Bisono® Tape 4 mg and Bisono® Tape 8 mg were improved to increase adhesive strength for better water resistance. 

Through the additional launch of Bisono® Tape 2 mg, TOA EIYO and Astellas expect that Bisono® Tape will further contribute to improvement in medication adherence and in treatment of patients suffering from atrial fibrillation who have difficulties in swallowing oral medication.

Contact the Media Relations team
Corporate Advocacy & Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)